Zenas BioPharma (ZBIO) Highlights New Clinical Data, Is It Still 52% Below Fair Value?

Conference spotlight on Zenas BioPharma

Zenas BioPharma (ZBIO) is back in focus after the company highlighted new clinical data for orelabrutinib and obexelimab at a major neurology meeting and scheduled a separate pipeline-focused R&D event.

Recent trading has been choppy. Zenas BioPharma’s share price is up 4.6% over the last day and 4.5% across the past week, yet remains down 18.3% year to date. The 1 year total shareholder return of 8.8% suggests that sentiment has been rebuilding as clinical milestones such as the neurology conference data and the upcoming R&D event refocus attention on the pipeline.

Scan other immunology and biotech names that could be setting up for similar catalyst-driven moves using our hand picked list of 20 high quality undiscovered gems

.

After a 1 day bounce and a year to date decline, Zenas BioPharma now trades at a steep 30% plus discount to analyst targets. Is that a valuation gap or a warning label as losses continue?

Most Popular Narrative: 52% Undervalued

On the most followed narrative, Zenas BioPharma’s fair value of $59 sits well above the last close at $28.18. This puts the conference headlines and fresh data in the context of a much bigger long term story built around IgG4-RD and autoimmune neurology.

A broad pipeline that includes the oral IL-17 inhibitor ZB021 and the brain penetrant TYK2 inhibitor ZB022, combined with a cash balance of about US$674 million and additional accessible funding, allows Zenas BioPharma to advance multiple programs toward proof of concept without near term equity raises. This can influence future earnings per share through both potential new revenue lines and reduced financing costs.

See why 1 investors see Zenas BioPharma as 52% undervalued.

Result: Fair Value of $59 (UNDERVALUED)

Still, the bullish Zenas BioPharma narrative leans heavily on successful obexelimab execution, while rising quarterly losses and ongoing funding needs could quickly challenge that optimism.

Find out about the key risks to this Zenas BioPharma narrative.

Next Steps

Mixed feelings about Zenas BioPharma so far. If you want to move quickly from headline to conviction, start by weighing its 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Zenas BioPharma?

Do not stop at Zenas BioPharma if you want a fuller watchlist. Broaden your options with targeted screens that surface stocks aligned with how you like to invest.

• Target potential mispricings by reviewing companies flagged as high potential value ideas in the 29 high quality undervalued stocks.
• Build a steadier foundation by focusing on businesses with strong finances using the list of solid balance sheet and fundamentals (25 results).
• Prioritise resilience and capital protection by scanning for companies highlighted in the 31 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com